Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| Relmada Therapeutics Inc.COM | COM | $50.9M | 15.8% |
| C4 Therapeutics Inc.COM STK | COM STK | $33.6M | 10.4% |
| Cogent Biosciences Inc.COM | COM | $33.5M | 10.4% |
| Kodiak Sciences Inc.COM | COM | $19.5M | 6.0% |
| Relay Therapeutics Inc.COM | COM | $18.1M | 5.6% |
| Zentalis Pharmaceuticals Inc.COM | COM | $17.9M | 5.6% |
| Edgewise Therapeutics Inc.COM | COM | $11.8M | 3.7% |
| Maze Therapeutics Inc.COM | COM | $10M | 3.1% |
| Inventiva SAADS | ADS | $9.2M | 2.9% |
| Adlai Nortye LtdSPONSORED ADS | SPONSORED ADS | $8.8M | 2.7% |
| Enliven Therapeutics Inc.COM | COM | $8.12M | 2.5% |
| Arrivent Biopharma Inc. (call option)COM | COM | $6.36M | 2.0% |
| Palisade Bio Inc.COM | COM | $6.27M | 1.9% |
| Bioage Labs Inc. (call option)COM | COM | $6.13M | 1.9% |
| Inhibikase Therapeutics Inc.COM NEW | COM NEW | $6.09M | 1.9% |
| Adagene Inc.ADS | ADS | $5.25M | 1.6% |
| Forte Biosciences Inc.COM NEW | COM NEW | $4.78M | 1.5% |
| Rezolute Inc. (call option)COM NEW | COM NEW | $4.68M | 1.5% |
| Inflarx NVCOM | COM | $4.48M | 1.4% |
| Assembly Biosciences Inc.COM NEW | COM NEW | $4.4M | 1.4% |
| Compass Pathways PLC (call option)SPONSORED ADS | SPONSORED ADS | $4.32M | 1.3% |
| Promis Neurosciences Inc.COM SHS | COM SHS | $4.28M | 1.3% |
| Contineum Therapeutics Inc.CL A | CL A | $4.26M | 1.3% |
| Compass Pathways PLCSPONSORED ADS | SPONSORED ADS | $4.25M | 1.3% |
| Definium Therapeutics Inc.COM SHS | COM SHS | $4M | 1.2% |
| Sol-gel Technologies LtdSHS NEW | SHS NEW | $3.86M | 1.2% |
| Bioage Labs Inc.COM | COM | $3.8M | 1.2% |
| Scynexis Inc.COM | COM | $3.08M | 1.0% |
| Proqr Thrapeutics N VSHS EURO | SHS EURO | $2.81M | 0.9% |
| Disc Medicine Inc. (call option)COM | COM | $2.19M | 0.7% |
| Rezolute Inc.COM NEW | COM NEW | $2.1M | 0.7% |
| Lipocine Inc. NewCOM NEW | COM NEW | $2.07M | 0.6% |
| Zentalis Pharmaceuticals Inc. (call option)COM | COM | $2.07M | 0.6% |
| C4 Therapeutics Inc. (call option)COM STK | COM STK | $1.87M | 0.6% |
| Ultragenyx Pharmaceutical IN (call option)COM | COM | $1.84M | 0.6% |
| Cue Biopharma Inc.COM | COM | $1.58M | 0.5% |
| Calcimedica Inc.COM NEW | COM NEW | $1.28M | 0.4% |
| Quince Therapeutics Inc.COM | COM | $734K | 0.2% |
| Nuvectis Pharma Inc. (call option)COM | COM | $712K | 0.2% |
| Pasithea Therapeutics Corp.COM NEW | COM NEW | $515K | 0.2% |
| Inmed Pharmaceuticals Inc.COM NEW | COM NEW | $504K | 0.2% |
| Neumora Therapeutics Inc..COM | COM | $170K | 0.1% |
| Nextcure Inc.COM NEW | COM NEW | $103K | 0.0% |
Relmada Therapeutics Inc.COM$50.9M
- Class
- COM
- Share
- 15.8%
C4 Therapeutics Inc.COM STK$33.6M
- Class
- COM STK
- Share
- 10.4%
Cogent Biosciences Inc.COM$33.5M
- Class
- COM
- Share
- 10.4%
Kodiak Sciences Inc.COM$19.5M
- Class
- COM
- Share
- 6.0%
Relay Therapeutics Inc.COM$18.1M
- Class
- COM
- Share
- 5.6%
Zentalis Pharmaceuticals Inc.COM$17.9M
- Class
- COM
- Share
- 5.6%
Edgewise Therapeutics Inc.COM$11.8M
- Class
- COM
- Share
- 3.7%
Maze Therapeutics Inc.COM$10M
- Class
- COM
- Share
- 3.1%
Inventiva SAADS$9.2M
- Class
- ADS
- Share
- 2.9%
Adlai Nortye LtdSPONSORED ADS$8.8M
- Class
- SPONSORED ADS
- Share
- 2.7%
Enliven Therapeutics Inc.COM$8.12M
- Class
- COM
- Share
- 2.5%
Arrivent Biopharma Inc. (call option)COM$6.36M
- Class
- COM
- Share
- 2.0%
Palisade Bio Inc.COM$6.27M
- Class
- COM
- Share
- 1.9%
Bioage Labs Inc. (call option)COM$6.13M
- Class
- COM
- Share
- 1.9%
Inhibikase Therapeutics Inc.COM NEW$6.09M
- Class
- COM NEW
- Share
- 1.9%
Adagene Inc.ADS$5.25M
- Class
- ADS
- Share
- 1.6%
Forte Biosciences Inc.COM NEW$4.78M
- Class
- COM NEW
- Share
- 1.5%
Rezolute Inc. (call option)COM NEW$4.68M
- Class
- COM NEW
- Share
- 1.5%
Inflarx NVCOM$4.48M
- Class
- COM
- Share
- 1.4%
Assembly Biosciences Inc.COM NEW$4.4M
- Class
- COM NEW
- Share
- 1.4%
Compass Pathways PLC (call option)SPONSORED ADS$4.32M
- Class
- SPONSORED ADS
- Share
- 1.3%
Promis Neurosciences Inc.COM SHS$4.28M
- Class
- COM SHS
- Share
- 1.3%
Contineum Therapeutics Inc.CL A$4.26M
- Class
- CL A
- Share
- 1.3%
Compass Pathways PLCSPONSORED ADS$4.25M
- Class
- SPONSORED ADS
- Share
- 1.3%
Definium Therapeutics Inc.COM SHS$4M
- Class
- COM SHS
- Share
- 1.2%
Sol-gel Technologies LtdSHS NEW$3.86M
- Class
- SHS NEW
- Share
- 1.2%
Bioage Labs Inc.COM$3.8M
- Class
- COM
- Share
- 1.2%
Scynexis Inc.COM$3.08M
- Class
- COM
- Share
- 1.0%
Proqr Thrapeutics N VSHS EURO$2.81M
- Class
- SHS EURO
- Share
- 0.9%
Disc Medicine Inc. (call option)COM$2.19M
- Class
- COM
- Share
- 0.7%
Rezolute Inc.COM NEW$2.1M
- Class
- COM NEW
- Share
- 0.7%
Lipocine Inc. NewCOM NEW$2.07M
- Class
- COM NEW
- Share
- 0.6%
Zentalis Pharmaceuticals Inc. (call option)COM$2.07M
- Class
- COM
- Share
- 0.6%
C4 Therapeutics Inc. (call option)COM STK$1.87M
- Class
- COM STK
- Share
- 0.6%
Ultragenyx Pharmaceutical IN (call option)COM$1.84M
- Class
- COM
- Share
- 0.6%
Cue Biopharma Inc.COM$1.58M
- Class
- COM
- Share
- 0.5%
Calcimedica Inc.COM NEW$1.28M
- Class
- COM NEW
- Share
- 0.4%
Quince Therapeutics Inc.COM$734K
- Class
- COM
- Share
- 0.2%
Nuvectis Pharma Inc. (call option)COM$712K
- Class
- COM
- Share
- 0.2%
Pasithea Therapeutics Corp.COM NEW$515K
- Class
- COM NEW
- Share
- 0.2%
Inmed Pharmaceuticals Inc.COM NEW$504K
- Class
- COM NEW
- Share
- 0.2%
Neumora Therapeutics Inc..COM$170K
- Class
- COM
- Share
- 0.1%
Nextcure Inc.COM NEW$103K
- Class
- COM NEW
- Share
- 0.0%
The share class is shown on a wider screen.
The 43 largest of 43 positions by value, with holdings of the same security combined. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 2050709
- File number
- 028-26573
- Options
- 9 call, 0 put
- In the 25 largest
- 90.3%
- Prior quarter
- $273M at 31 March 2026
- Positions opened
- 24
- Positions closed
- 18
Common questions
What are Squadron Capital Management’s 13F holdings worth?
$322 million across 43 positions for the quarter ended 30 June 2026.
What is Squadron Capital Management’s largest 13F holding?
RELMADA THERAPEUTICS INC (COM) was the largest position at $50.9 million, or 15.8% of reported 13F value, as of 30 June 2026.
How concentrated is Squadron Capital Management’s 13F portfolio?
The ten largest positions accounted for 66.2% of reported value and the twenty-five largest for 90.3%, across 43 positions as of 30 June 2026.
Does Form 13F show everything Squadron Capital Management manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Squadron Capital Management file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.